OPTION: A Trial to Assess the Safety & Efficacy of MS1819 in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
Conditions: Exocrine Pancreatic Insufficiency (EPI); Cystic Fibrosis (CF) Interventions: Drug: MS1819-SD; Drug: Porcine PERT Sponsor: AzurRx BioPharma, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials